OncLive | Bringing the Global Oncology Community Together

Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors... Read More >>

SABCS 2019: Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

SABCS 2019: ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC

SABCS 2019: Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes

Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups

SABCS 2019: Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

View More Stories >>

View Conference Coverage

2019 San Antonio Breast Cancer Symposium

2019 ASH Annual Meeting

2019 International Congress of the Society for Melanoma Research

2019 State of the Science Summit on Genitourinary Cancers in Nashville

2019 State of the Science Summit on Hematologic Malignancies in Chicago

Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies

Dr. Danilov on Utility of Rituximab Biosimilars in CLL

Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in Melanoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Frontline and R/R Therapy and PD-L1 Targeted Therapy for SCLC

Emerging Therapies for Extensive Stage SCLC and CASPIAN Trial

The ADRIATIC Trial in Limited-Stage SCLC

The CASPIAN Trial in Extensive-Stage SCLC

ClarIDHy Phase III Trial of Ivosidenib in CCA

OncLive houses thousands of videos that provide updates and information.
See more Videos

Important Considerations When Diagnosing NETs

LIBRETTO-001 Regimen Overview

RET Testing in Papillary and Medullary Thyroid Cancer

RET Treatment: Novel Compounds to Replace Current TKIs

Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

RET Fusion, Point Mutation, and Signaling

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

Role of the BCL-2 Pathway in Acute Myeloid Leukemia

Overexpression of pro-survival BCL-2 family regulator proteins is an important driver of resistance to cell death in acute myeloid leukemia (AML). Accordingly, the BCL-2 pathway has emerged as an attractive research target for novel therapies.

View more >>>

Featured

Emerging MOAs in Multiple Myeloma: Updates From the 17th IMW

Data and analysis shared at the 17th International Myeloma Workshop show that anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates have the potential to revolutionize the multiple myeloma treatment paradigm.

View more >>>

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

OncLive News Network On Location: ASH 2019 Day 3